Discover and read the best of Twitter Threads about #ASCO21
Most recents (17)
@TumorBoardTues 1/17 #TumorBoardTuesday #LCSM #OncTwitter
50y 👩🏻 never 🚬 presents with cough
🩻CT: 2cm RLL 🫁 mass & pleural effusion
💧Tap of pleural fluid: adenocarcinoma TTF1+ (T1bN0M1a) Stage 4A #NSCLC
🧪NGS: exon19 deletion EGFR mutation & PDL1 70%+
🤨What’s most appropriate initial tx?
50y 👩🏻 never 🚬 presents with cough
🩻CT: 2cm RLL 🫁 mass & pleural effusion
💧Tap of pleural fluid: adenocarcinoma TTF1+ (T1bN0M1a) Stage 4A #NSCLC
🧪NGS: exon19 deletion EGFR mutation & PDL1 70%+
🤨What’s most appropriate initial tx?
@TumorBoardTues 2/17 #TumorBoardTuesday #LCSM
👩🏻 starts osimertinib with resolution of effusion
She has🧴dry skin & occasional 💩diarrhea managed with loperamide
After 18 months she develops headache
🧲MRI brain shows new 2cm 🧠 metastasis with edema
🤨What’s the most appropriate next step?
👩🏻 starts osimertinib with resolution of effusion
She has🧴dry skin & occasional 💩diarrhea managed with loperamide
After 18 months she develops headache
🧲MRI brain shows new 2cm 🧠 metastasis with edema
🤨What’s the most appropriate next step?
@TumorBoardTues 3/17 #TumorBoardTuesday #LCSM
👨🏼🏫Mini tweetorial 1
EGFR mutations
📍≈15% of🫁adenocarcinomas
📍More common in light or never smokers, women, & Asian ethnicity
📍90% sensitizing & either exon19 del/ins or L858R mut in exon21
@NatureRevCancer Sharma et al
nature.com/articles/nrc20…
👨🏼🏫Mini tweetorial 1
EGFR mutations
📍≈15% of🫁adenocarcinomas
📍More common in light or never smokers, women, & Asian ethnicity
📍90% sensitizing & either exon19 del/ins or L858R mut in exon21
@NatureRevCancer Sharma et al
nature.com/articles/nrc20…
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @ASCO @JCO_ASCO @MLJohnsonMD2 @BurrisSkip @RielyMD @JustinGainor @ChiFuJeffYang @ECarcereny @anguspratt @KRASKickers @thenasheffect @ALKpositiveINT @EgidiusLambrech @EugeneManley @ipreeshagul @JoelNealMD @HwakeleeMD @GlopesMd @jmsuga #TumorBoardTuesday
Some of tonight’s conversation will be discussing of multiple treatments of stage 3 #NSCLC.
My COI: I’m a consultant with @AstraZeneca, but thoughts are my own.
Some of tonight’s conversation will be discussing of multiple treatments of stage 3 #NSCLC.
My COI: I’m a consultant with @AstraZeneca, but thoughts are my own.
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @ASCO @JCO_ASCO @MLJohnsonMD2 @BurrisSkip @RielyMD @JustinGainor @ChiFuJeffYang @ECarcereny @anguspratt @KRASKickers @thenasheffect @ALKpositiveINT @EgidiusLambrech @EugeneManley @ipreeshagul @JoelNealMD @HwakeleeMD @GlopesMd @jmsuga @AstraZeneca 1/13 #TumorBoardTuesday #NSCLC #OncTwitter
65yo 🧔🏽, former 🚬, pmhx🫀 MI with stents
🩻CT: 🫁 right middle lobe mass & adenopathy
EBUS confirms adenocarcinoma level 7, 4R and the mass
🔬Molecular test: KRAS G12C & STK11 mutations, TMB 10, PD-L1 40% by 22C3.
Final stage T3N2M0
65yo 🧔🏽, former 🚬, pmhx🫀 MI with stents
🩻CT: 🫁 right middle lobe mass & adenopathy
EBUS confirms adenocarcinoma level 7, 4R and the mass
🔬Molecular test: KRAS G12C & STK11 mutations, TMB 10, PD-L1 40% by 22C3.
Final stage T3N2M0
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @ASCO @JCO_ASCO @MLJohnsonMD2 @BurrisSkip @RielyMD @JustinGainor @ChiFuJeffYang @ECarcereny @anguspratt @KRASKickers @thenasheffect @ALKpositiveINT @EgidiusLambrech @EugeneManley @ipreeshagul @JoelNealMD @HwakeleeMD @GlopesMd @jmsuga @AstraZeneca 2/13 #TumorBoardTuesday #LCSM #NSCLC
Multi-D Tumor Board discussion about 👆🏽patient.
🧐 Is an STK11 mutation taken into consideration?
🤨 What would you recommend as a treatment option?
Multi-D Tumor Board discussion about 👆🏽patient.
🧐 Is an STK11 mutation taken into consideration?
🤨 What would you recommend as a treatment option?
Here are my Top 5 #ASCO22 @ASCO myeloma abstracts. #ASCO22VR
Links to the full abstract. As in the past, I left out studies where similar results were already presented or published before. Top 5 based on new data, clinical impact & methodology
Thread with countdown👇
Links to the full abstract. As in the past, I left out studies where similar results were already presented or published before. Top 5 based on new data, clinical impact & methodology
Thread with countdown👇
#5 Risk adapted maintenance: Len for standard risk & Len plus Bortezomib for high risk gives outstanding results. #ASCO22 #ASCO22VR
Clinically important & updated data are excellent. @RujulParikh @SagarLonialMD @AjayNookaMD @WinshipAtEmory meetings.asco.org/abstracts-pres…
Clinically important & updated data are excellent. @RujulParikh @SagarLonialMD @AjayNookaMD @WinshipAtEmory meetings.asco.org/abstracts-pres…
#4 CAR-T targeting GPRC5D. Doubt if one BCMA approach fails another BCMA approach will give significant benefit. These treatments are incredibly expensive. We need immunotherapy options that target something besides BCMA. @ZJU_China
#ASCO22 #ASCO22VR meetings.asco.org/abstracts-pres…
#ASCO22 #ASCO22VR meetings.asco.org/abstracts-pres…
1/ On the heels of @ASCO #ASCO21 plenary, we are happy to share the results of KEYNOTE-564 trial of adjuvant pembrolizumab in mRCC just published in @NEJM ! A step towards better outcomes for all our patients with kidney cancer!
nejm.org/doi/full/10.10…
@OncoAlert @tompowles1
nejm.org/doi/full/10.10…
@OncoAlert @tompowles1
2/ Following nephrectomy for kidney cancer, a significant percentage of patients will experience disease recurrence, most of them with distant metastases, highlighting the need for effective adjuvant therapies.
3/ Despite many decades of research and clinical investigations, there are currently no globally approved adjuvant regimens for the management of #kidneycancer
@TumorBoardTues 52 yo 🚺 w/ rectal bldg. Cscope: rectal tumor at 5 cm from anal verge; bx: adenocarcinoma. Scans with T3bN1 rectal primary, liver mets (dMMR). How to treat?
@TumorBoardTues Given KN-177 data (PFS, PFS2 advantage but no OS benefit to 1L pembro due to crossover), and CheckMate 142 data of nivo/ipi, we decided to give nivo/ipi after TB discussion. Thoughts on pembro vs nivo/ipi??
About to watch @realrickpazdur on @statnews #ASCO21 recap.
Pazdur is one of thoe FDA voices that silences the room when he pipes up. When he speaks, you listen.
Pazdur is one of thoe FDA voices that silences the room when he pipes up. When he speaks, you listen.
@realrickpazdur @statnews .@realrickpazdur: People want to put regulations that don’t exist on us. For exmaple, we have to demonstrate that drug is safe and effective not that it is better than what we approved yesterday.
@realrickpazdur @statnews .@realrickpazdur: People must undersatnd we have to move on from the traditional overall survival endpoint to meet patients needs. #ASCO21
My take on #ASCO21 plenary data on adjuvant pembrolizumab for #kidneycancer: Promising DFS results are a good start. It is not surprising that OS is immature. This could very well be the way we treat high-risk localized RCC pts post-nephrectomy in the future. 1/4
9% abs diff in 24 month DFS, corresponds to NNT of 10-11. For stage III melanoma (pembro vs placebo - KEYNOTE-054), abs diff in 24 month RFS was 15-20% depending on stage (NNT 5-6). This will be a nuanced decision in clinic with lots of personalized risk-benefit discussion. 2/4
It would be really helpful to have biomarkers for IO toxicity. G3 treatment-related tox 18% with pembro, 7% required high dose steroids. Continued efforts to identify those most likely to have toxicity (or most likely to benefit) will help us to tailor therapy. 3/4
With one day for the dust to settle, here are my thoughts on some of the #ASCO21 #melanoma data.
1) It is interesting to me that no adj PD-1 melanoma study has yet shown OS benefit vs comparator arm (CM238 - nivo vs ipi, S1404 - pembro vs HDI or ipi, KN054- pembro vs placebo).
1) It is interesting to me that no adj PD-1 melanoma study has yet shown OS benefit vs comparator arm (CM238 - nivo vs ipi, S1404 - pembro vs HDI or ipi, KN054- pembro vs placebo).
Is this because more time in f/u is needed to see diffs emerge? Or does it suggest that PD-1 is equally effective regardless of disease setting (adj vs metastatic) and that enough pts with metastatic melanoma have durable long-term control on PD-1 to explain lack of OS benefit?
I suspect that PD-1 does cure some melanoma pts in the adjuvant setting. But are these the same pts that would have been cured in the metastatic setting? Not easy to answer but longer f/u of these three pivotal studies will be very important.
☕️ Since I’ve been seeing a lot of debate in the field lately, I’ve decided to provide a set of Guidelines for the management of a good 🇮🇹 coffee
1️⃣st - get a Moka. Better if an old one: just as wine, it gets better with the passing of time. Wash the Moka. Open the Moka.
[1/5]
1️⃣st - get a Moka. Better if an old one: just as wine, it gets better with the passing of time. Wash the Moka. Open the Moka.
[1/5]
2️⃣nd - Pour some water in the Moka. The right amount.
If you put too much, you get colored water 💧 . If you put to little, you’ve got no coffee to offer to other people. 🤷🏻♂️
Best is to reach just under the tiny valve. No rocket science.
[2/5]
If you put too much, you get colored water 💧 . If you put to little, you’ve got no coffee to offer to other people. 🤷🏻♂️
Best is to reach just under the tiny valve. No rocket science.
[2/5]
3️⃣rd - I call this step “The Everest”.
In short, put on the filter as much coffee as it fits. Then you add some more. And then some more.
❌DO NOT PRESS.
Coffee doesn’t like to get pressed. Nobody does.
Just make it gently fall from above, & make the mountain appear ⛰
[3/5]
In short, put on the filter as much coffee as it fits. Then you add some more. And then some more.
❌DO NOT PRESS.
Coffee doesn’t like to get pressed. Nobody does.
Just make it gently fall from above, & make the mountain appear ⛰
[3/5]
The OlympiA trial is being discussed on social media a lot. It’s been presented at #ASCO21 and the paper has come out in @NEJM (along with appendices). Since PROfound, I’ve approached Olaparib trials with a degree of healthy skepticism. But this seems promising.
Main problems are:
- Interim analysis at only 2.5y follow up, so don’t jump to conclusions yet. Need to know whether olaparib really increases cure rate, or just delays recurrence.
- No comparison against adjuvant cape (CREATE-X) which is current SoC.
- Very expensive treatment!
- Interim analysis at only 2.5y follow up, so don’t jump to conclusions yet. Need to know whether olaparib really increases cure rate, or just delays recurrence.
- No comparison against adjuvant cape (CREATE-X) which is current SoC.
- Very expensive treatment!
This is too early, right?
Thread (?#) highlighting this remarkable session: DISMANTLING GENDER DISPARITIES IN THE GLOBAL ONCOLOGY WORKFORCE TOGETHER.
Really, what else are you even watching today #ASCO21!?! /1
Really, what else are you even watching today #ASCO21!?! /1
First off—it is sooooo timely. ⏰
H/T @AlexCarolanTCL @TheCancerLetter /2 #ASCO21
cancerletter.com/the-cancer-let…
H/T @AlexCarolanTCL @TheCancerLetter /2 #ASCO21
cancerletter.com/the-cancer-let…
.@PamelaKunzMD starts by sharing the #ASCO20 team decided to postpone session b/c it was so important to them. And they really wanted to get MEN in the room. ❤️that #heforshe leadership, @BurrisSkip; See the influence of @MLJohnsonMD2 and @tmprowell all over this! #ASCO21 /3
Hi, #ASCO21 world. As you get bombarded with news of the remarkable new therapies, I request you to kindly read these 3 papers to put things into context.
1. Trials that are flawed in design, analysis, and interpretation can give false signal of benefit- esmoopen.com/article/S2059-… 1
1. Trials that are flawed in design, analysis, and interpretation can give false signal of benefit- esmoopen.com/article/S2059-… 1
2. Drugs that are claimed to be "well-tolerated" or having a "favourable" or "Acceptable" toxicity profiles are usually not so. These are almost misnomers. Look into the safety data yourself. bmj.com/content/363/bm… 2
Patients in LMICs are still dying not because they didn't have access to the newest checkpoint inhibitor but because they didn't have access to surgery/radiation/pathology/chemo and other basic services. #cancergroundshot #globaloncology thelancet.com/journals/lanon…
#ASCO21 MM abstracts of note in no particular order with my thoughts
@mtmdphd @End_myeloma @bhemato @BldCancerDoc @adsouza_md
@mtmdphd @End_myeloma @bhemato @BldCancerDoc @adsouza_md
Frigault et al. ddBCMA – novel nonscFV binding enabled CAR-T (ARC-101) – 100% ORR (N-10)
meetinglibrary.asco.org/record/195469/… Promising and new CARs will give bispecifics a run for their money.
meetinglibrary.asco.org/record/195469/… Promising and new CARs will give bispecifics a run for their money.
Berdeja et al Talquetamab truly novel GPRC5D bispecific – N-172 and RP2D established for SC; CRS 75%; skin; nail effects and dysgeusia. ORR 65%; 50% VGPR and even in pentarefr
meetinglibrary.asco.org/record/195432/…
meetinglibrary.asco.org/record/195432/…
In no particular order, 5 abstracts that caught my eye as a GI oncologist preparing for #ASCO21
KEYNOTE-177:
meetinglibrary.asco.org/record/195775/…
#crcsm
1/
KEYNOTE-177:
meetinglibrary.asco.org/record/195775/…
#crcsm
1/
#ASCO21
🙏Thank you all for the positive feedback on the PDAC Abstracts
➡️Here now is my 2nd list
✅My Top NON-Pancreatic abstracts to watch for...in no particular order.....
📝Again, I tagged who I could (whose hashtag I could find)
🙏Thank you all for the positive feedback on the PDAC Abstracts
➡️Here now is my 2nd list
✅My Top NON-Pancreatic abstracts to watch for...in no particular order.....
📝Again, I tagged who I could (whose hashtag I could find)
#ASCO21
There were several potential practice changing studies including the one Late Breaking Abstract teaser:
➡️I Chau, et al (LBA 4001)
✅Nivo + ipi or Nivo + chemo vs. chemo alone as 1st-line Tx for esophageal SCC: CheckMate 648
🧐Will dual IO be the winner❓
There were several potential practice changing studies including the one Late Breaking Abstract teaser:
➡️I Chau, et al (LBA 4001)
✅Nivo + ipi or Nivo + chemo vs. chemo alone as 1st-line Tx for esophageal SCC: CheckMate 648
🧐Will dual IO be the winner❓
#ASCO21
➡️R-H Xu, et al (abstr 4000)
✅Ph 3 trial of camrelizumab plus chemo vs. chemo in patients with advanced esophageal SCC
👉Paclitaxel + cis +/- camrelizumab
👉596 patients randomized
🎉Camrelizumab plus chemotherapy⬆️mOS (15.3 vs. 12.0 mos) and ⬆️ORR (72.1% vs. 62.1%)
➡️R-H Xu, et al (abstr 4000)
✅Ph 3 trial of camrelizumab plus chemo vs. chemo in patients with advanced esophageal SCC
👉Paclitaxel + cis +/- camrelizumab
👉596 patients randomized
🎉Camrelizumab plus chemotherapy⬆️mOS (15.3 vs. 12.0 mos) and ⬆️ORR (72.1% vs. 62.1%)
#ASCO21 #PancreaticCancer
📢ASCO is a few days away, and I decided to put together my list of
✅Top Abstracts to watch for
📝I tagged who I could
Starting with my Top Pancreatic Cancer Abstracts...in no particular order.....
(A common theme: NGS and fusion testing is🗝️)
📢ASCO is a few days away, and I decided to put together my list of
✅Top Abstracts to watch for
📝I tagged who I could
Starting with my Top Pancreatic Cancer Abstracts...in no particular order.....
(A common theme: NGS and fusion testing is🗝️)
#ASCO21 #PancreaticCancer
@VivekSubbiah, et al (Abstr 3079)
➡️RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors
I know - he has presented this before🙄
🥳but now 3/3 patients with pancreatic cancer responded - one with a CR ongoing at 20.8 months‼️
@VivekSubbiah, et al (Abstr 3079)
➡️RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors
I know - he has presented this before🙄
🥳but now 3/3 patients with pancreatic cancer responded - one with a CR ongoing at 20.8 months‼️
#ASCO21 #PancreaticCancer
Alison M. Schram, @EileenMOReilly @graokane @benweinbergmd (abstr 3003)
➡️Zenocutuzumab (MCLA-128) in pancreas cancer and other solid tumors harboring NRG1 fusions
✅INV-assessed ORR = 40% (4/10)
✅Tumor regression in 7/10 pts
✅DCR = 90%
✅DOR TBD
Alison M. Schram, @EileenMOReilly @graokane @benweinbergmd (abstr 3003)
➡️Zenocutuzumab (MCLA-128) in pancreas cancer and other solid tumors harboring NRG1 fusions
✅INV-assessed ORR = 40% (4/10)
✅Tumor regression in 7/10 pts
✅DCR = 90%
✅DOR TBD
Here are my Top 5 #ASCO21 @ASCO myeloma abstracts. #ASCO21VR
I’ve listed them with links to the full abstract. @mtmdphd @Rfonsi1 @MayoMyeloma @chadinabhan @Mohty_EBMT @BldCancerDoc @szusmani @NBahlis @NoopurRajeMD @profghjackson @contirena1 @DusetzinaS
Thread for countdown👇
I’ve listed them with links to the full abstract. @mtmdphd @Rfonsi1 @MayoMyeloma @chadinabhan @Mohty_EBMT @BldCancerDoc @szusmani @NBahlis @NoopurRajeMD @profghjackson @contirena1 @DusetzinaS
Thread for countdown👇
#5 Daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd) for ultra high risk MM and plasma cell leukemia. A modern alternative to VDT-PACE. 94% response rate. @profghjackson @MyelomaUK #ASCO21VR #ASCO21
meetinglibrary.asco.org/record/195431/…
meetinglibrary.asco.org/record/195431/…
#4 Financial difficulty in patients with multiple myeloma. 20% of patients reported financial difficulties in 1 year. Glad this is being studied. I do think this is an underestimate. @ALLIANCE_org @theNCI @contirena1 #ASCO21VR #ASCO21
meetinglibrary.asco.org/record/195456/…
meetinglibrary.asco.org/record/195456/…
